drugset / Trial / NCT05124028
A Study of Orelabrutinib in Patients With ITP
NaSingle-groupOpen-labelTreatment
Summary
This project was undertaken to evaluate the efficacy and safety of BTK inhibitor Orelabrutinib for the secondary treatment of adults with primary immune thrombocytopenia (ITP).
Timeline
- Start
- 2021-12-01
- Primary completion
- 2022-03-01
- Completion
- 2022-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Orelabrutinib | Small molecule | 50 mg | Oral |